Pelage key facts
as of Oct 2026- Provider of regenerative medicines intended to develop clinical-stage treatments for hair loss grounded in stem cell biology.
- Pelage is valued at approximately $323.0M as of Oct 2026 (last reported valuation).
- It has raised $150.8M; the latest was Accelerator/Incubator ($120.0M) in Oct 2025.
- Notable investors include GV, Novo Holdings, ARCH Venture Partners, Hawktail, Main Street Advisors — 9 tracked in total.
- Status: Privately Held (backing).
Pelage's last reported valuation, Oct 2025. Nothing priced has surfaced since.
- ·Watch Pelage: the Monday email on marks, rounds and moves
Pelage funding rounds
No funding rounds for Pelage are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Pelage valuation
Pelage's last reported valuation was $323 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.
Pelage investors
9 investors are on record for Pelage, including GV, Novo Holdings, ARCH Venture Partners and Hawktail.
About Pelage
Provider of regenerative medicines intended to develop clinical-stage treatments for hair loss grounded in stem cell biology. The company offers a topical small molecule program, clinical trials for androgenetic alopecia and other alopecia types, stem cell biology research, a regenerative medicine platform, and press-reported financing information, providing clients with advanced hair loss treatment programs.
- Sector
- Healthcare
- HQ
- Los Angeles, CA, United States
- Founded
- 2018
- Employees
- 10
- Website
- pelagepharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.